UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________________ to ____________________
Commission
File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Securities registered under Section 12(b) of the Exchange Act: None
Securities registered under Section 12(g) of the Exchange Act:
Indicate
by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
As of March 31, 2022, the registrant had shares of Common Stock outstanding.
TABLE OF CONTENTS
| 2 |
PART I – FINANCIAL INFORMATION
Item 1.Financial Information.
QUANTA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2022 | December 31, 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable | ||||||||
| Inventories | ||||||||
| Prepaid production cost | ||||||||
| Total current assets | ||||||||
| Equipment, net | ||||||||
| Operating lease right-of-use asset, net | ||||||||
| Deposits | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Advances | ||||||||
| Notes
payable (net of deferred finance charge of $ | ||||||||
| Convertible
note payable (net of discount of $ | ||||||||
| Deferred revenue, license agreement | ||||||||
| Operating lease liabilities, short-term | ||||||||
| Settlement Reserve | ||||||||
| Total current liabilities | ||||||||
| Long term liabilities | ||||||||
| Notes payable, long term | ||||||||
| Operating lease liabilities, long-term | ||||||||
| Total liabilities | ||||||||
Commitments and contingencies: | ||||||||
| Mezzanine equity: | ||||||||
| Series B preferred stock, $ par value, shares authorized, and -- issued and outstanding at March 31, 2021 and December 31, 2021, respectively | ||||||||
| Series C preferred stock, $ par value, shares authorized, and issued and outstanding at March 31, 2021 and December 31, 2021, respectively | ||||||||
| Total Mezzanine equity | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, $ par value; shares authorized; issued and outstanding | ||||||||
| Common stock, $ par value; shares authorized; and shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | ||||||||
| Shares to be issued ( and as of March 31, 2022 and December 31, 2021, respectively) | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Quanta, Inc. stockholders deficit | ( | ) | ( | ) | ||||
| Noncontrolling interest in consolidated subsidiary | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
See notes to condensed consolidated financial statements
| 3 |
QUANTA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three
months ended March 31, 2022 | Three
months ended March 31, 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Sales,
net (includes sales to related party of $ | $ | $ | ||||||
| License revenue | ||||||||
| Total revenue | ||||||||
| Cost of goods sold | ||||||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Employee compensation and contractors | ||||||||
| Selling,
general, and administrative (includes royalty of $ | ||||||||
| Research and development | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Discount amortization | ( | ) | ( | ) | ||||
| Other income and expense, net | ( | ) | ( | ) | ||||
| Net loss | ( | ) | ( | ) | ||||
| Net loss attributable to noncontrolling interest | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Net loss per share, basic and diluted | $ | ( | ) | $ | ( | ) | ||
| Weighted average common shares outstanding – basic and diluted | ||||||||
See notes to condensed consolidated financial statements
| 4 |
QUANTA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
Three months ended March 31, 2022 (Unaudited)
| Series
A Preferred Stock, par value $0.001 | Common
Stock par value $0.001 | Additional Paid-in | Shares To be | Accumulated |
Non Controlling | Total Stockholders’ | ||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Issued | Deficit | Interest | Deficit | ||||||||||||||||||||||||||||
| Balance December 31, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||
| Fair value of shares issued for services | - | |||||||||||||||||||||||||||||||||||
| Fair value of vested restricted shares | - | - | ||||||||||||||||||||||||||||||||||
| Shares issued for conversion of convertible notes | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance March 31, 2022 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||
| 5 |
Three months ended March 31, 2021 (Unaudited)
| Series
A Preferred Stock, par value $0.001 | Common
Stock par value $0.001 | Additional Paid-in | Shares To be | Accumulated | Non Controlling | Total Stockholders’ | ||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Issued | Deficit | Interest | Deficit | ||||||||||||||||||||||||||||
| Balance December 31, 2020 | $ | $ | $ | $ | $ | ( | ) | $ | $ | ( | ) | |||||||||||||||||||||||||
| Adjustment for adoption of ASU 2020-6 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Shares issued for cash | - | |||||||||||||||||||||||||||||||||||
| Fair value of vested options | - | - | ||||||||||||||||||||||||||||||||||
| Fair value of shares issued to employees and officers | - | |||||||||||||||||||||||||||||||||||
| Fair value of restricted shares | - | - | ||||||||||||||||||||||||||||||||||
| Shares issued for conversion of convertible notes | - | |||||||||||||||||||||||||||||||||||
| Net loss | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance March 31, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||
| 6 |
QUANTA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Three
Months Ended March 31, 2022 | Three
Months Ended March 31, 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| CASH FLOW FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | ||||||||
| Fair value of shares issued for services | ||||||||
| Fair value of vested options | ||||||||
| Fair value of vested restricted shares | ||||||||
| Fair value of Series B preferred shares issued to officer | ||||||||
| Amortization of convertible note discount | ||||||||
| Amortization of note payable discount | ||||||||
| Amortization of right-of-use asset | ||||||||
| Fees paid through conversion of convertible notes | ||||||||
| Net loss attributable to noncontrolling interest | ( | ) | ( | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Accounts receivable, related party | ( | ) | ||||||
| Allowance for doubtful accounts | ||||||||
| Deferred expenses, related party | ||||||||
| Inventories | ( | ) | ||||||
| Prepaid production costs | ( | ) | ||||||
| Accounts payable and accrued liabilities | ( | ) | ||||||
| Deferred revenue | ( | ) | ( | ) | ||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOW FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of equipment | ( | ) | ||||||
| Net cash used in investment activities | ( | ) | ||||||
| CASH FLOW FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from convertibles notes payable | ||||||||
| Proceeds from notes payable | ||||||||
| Principal payments on convertible notes payable | ( | ) | ( | ) | ||||
| Principal payments on notes payable | ( | ) | ||||||
| Proceeds from shares issued for cash | ||||||||
| Net cash provided by financing activities | ||||||||
| Increase (decrease) in cash | ( | ) | ||||||
| Cash and cash equivalents, beginning of period | ||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental Disclosures of Cash Flow Information: | ||||||||
| Cash paid for taxes | ||||||||
| Cash paid for interest | ||||||||
| Non-cash investing and financing activities | ||||||||
| Adjustment for adoption of ASU 2020-06 | ||||||||
| Common shares issued for conversion of convertible notes | ||||||||
See notes to condensed consolidated financial statements
| 7 |
QUANTA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (UNAUDITED)
NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Quanta, Inc. (the “Company”) is an applied science company focused on a range of pharmaceutical, nutraceutical, topical relief and cosmetic products utilizing patented polarization technology. The Company’s operations are based in Burbank, California. On April 28, 2016, the Company was incorporated as Freight Solution, Inc. in the State of Nevada. Effective June 6, 2018, the Company (then known as Bioanomaly Inc.) was acquired by Freight Solution in a transaction accounted for as a reverse merger transaction. On July 11, 2018, the Company changed its name to Quanta, Inc.
On
December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife
Rx”) pursuant to which, the Company agreed to acquire
Basis of presentation-Unaudited Interim Financial Information
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods have been included. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2021 and notes thereto contained in the Annual Report on Form 10-K of the Company as filed with the SEC on April 15, 2022.
The
consolidated financial statements include the accounts of Quanta Inc, and its
Going Concern
The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement
of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the quarter
ended March 31, 2022, the Company incurred a net loss of $
At
March 31, 2022, the Company had cash on hand in the amount of $
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, allowance for doubtful accounts receivable, impairment analysis of long-term assets, valuation allowance on deferred income taxes, assumptions used in valuing stock instruments issued for services, assumptions made in valuing derivative liabilities, and the accrual of potential liabilities. Actual results may differ from these estimates.
Revenue recognition
The Company follows the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.
Product Sales—Substantially all of the Company’s revenue is derived from product sales. Product revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time.
License revenue— Revenue from symbolic IP is recognized over the access period to the Company’s IP (see Note 2).
| 8 |
Cost of goods sold includes direct costs and fees related to the sale of our products.
Convertible Notes with Fixed Rate Conversion Options
The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder, into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a premium, as applicable, on the Note date with a charge to interest expense in accordance with ASC 480 - “Distinguishing Liabilities from Equity”.
Stock-based compensation
The Company periodically issues stock options, warrants, shares of common stock, and restricted stock unit awards, as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation (Topic 718). Stock-based compensation cost for employees is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the requisite service period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.
The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.
Prepaid production costs
In
February 2021, the Company’s subsidiary Medolife Rx entered into a collaboration and joint development agreement with a company
(the “Agent) for Medolife to produce some of its products in the Agent’s facility. Medolife Rx agreed to pay the Agent $
Advertising costs
Advertising
costs are expensed as incurred. During the quarters ended March 31, 2022 and March 31, 2021, advertising costs totaled $
Research and Development Costs
Costs
incurred for research and development are expensed as incurred. During the quarters ended March 31, 2022 and March 31, 2021, research
and development costs totaled $
Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Shares used in the calculation of basic net loss per common share include vested but unissued shares underlying awards of restricted common stock. Diluted loss per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company. In computing diluted loss per share, the treasury stock method assumes that outstanding warrants and convertible notes are exercised and the proceeds are used to purchase common stock at the average market price during the period. Warrants and convertible notes may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants.
For the three months ended March 31, 2022 and 2021, the dilutive impact of common stock equivalents, e.g. stock options, warrants and convertible notes payable have been excluded from calculation of weighted average shares because their impact on the loss per share is anti-dilutive.
As
of March 31, 2022, options were outstanding of which were exercisable, and convertible debt and accrued interest totaling
$
| March 31, 2022 | March 31, 2021 | |||||||
| Stock options | ||||||||
| Unvested restricted shares | ||||||||
| Convertible notes payable | ||||||||
| Total | ||||||||
| 9 |
Fair Value of Financial Instruments
The Company follows the authoritative guidance issued by the Financial Accounting Standards Board (“FASB”) for fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
Level 3—Unobservable inputs based on the Company’s assumptions.
The Company is required to use of observable market data if such data is available without undue cost and effort.
The Company believes the carrying amount reported in the balance sheet for cash, accounts receivable, accounts payable and accrued liabilities, and notes payable, approximate their fair values because of the short-term nature of these financial instruments.
As of March 31, 2022 and December 31, 2021, the Company did not have any Level 2 liabilities comprised of the fair value of embedded derivative liabilities.
Concentrations of risks
For
the three months ended March 31, 2022, no customer accounted for
As
of March 31, 2022, two vendors accounted for
The Company maintains the majority of its cash balances with one financial institution, in the form of demand deposits that are insured by the Federal Deposit Insurance Corporation, or FDIC. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company has not experienced any losses in its cash and believes it is not exposed to any significant credit risk.
Segments
The
Company operates in
Recent Accounting Pronouncements
In
August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).” ASU 2020-06
reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion
accounting models. As a result, the Company’s convertible debt instruments will be accounted for as a single liability measured
at its amortized cost as long as no other features require bifurcation and recognition as derivatives. For contracts in an entity’s
own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as
derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. The Company
early adopted ASU No. 2020-06 effective January 1, 2021 using the modified retrospective approach. Upon adoption, the following changes
resulted: (i) the intrinsic value of the beneficial conversion feature recorded in 2020 was reversed as of the effective date of adoption,
thereby resulting in an increase in the convertible debentures with an offsetting adjustment to additional paid in capital and (ii) interest
expense recorded in 2020 that was related to the amortization of the discount related to the beneficial conversion feature was reversed
against opening accumulated deficit. Accordingly, the adoption of ASU 2020-06 resulted in a decrease to accumulated deficit of $
In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures.
Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
Accounts Receivable
Accounts receivable are recorded net of an allowance for any uncollectible accounts if deemed necessary, and payments are generally due within thirty to forty-five days of invoicing. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. At December 31, 2021 and December 31, 2020, the Company did not record any allowance for uncollectible accounts.
| 10 |
Inventories
Inventories
are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out (“FIFO”) basis. We
regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated
forecast of product demand and our ability to sell the product(s) concerned. Demand for our products can fluctuate significantly. Additionally,
our management’s estimates of future product demand may be inaccurate, which could result in an understated or overstated provision
required for excess and obsolete inventory. A reserve for raw materials, product obsolescence and packaging for products that may no
longer be viable of $
Equipment
Equipment is stated at cost less accumulated depreciation. Depreciation is provided over the estimated useful lives of the equipment, which is three years, using the straight-line method. Expenditures for major additions and improvements are capitalized and minor repairs and maintenance are charged to expense as incurred. When equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period.
Management assesses the carrying value of equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. For the years ended December 31, 2021 and 2020, the Company determined there were no indicators of impairment of its property and equipment.
Impairment of Long-lived Assets
The
Company reviews its equipment, right-of-use assets, and other long-lived assets, for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying
amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an
asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount
of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted
cash flows or market value, if readily determinable. For the years ended December 31, 2021 and 2020, the Company had
Leases
The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments The Company adopted ASC 842 on January 1, 2019. There was no cumulative-effect adjustment to accumulated deficit (see Note 5).
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2021, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Income taxes
The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.
NOTE 2 – INVENTORIES
Inventories are valued at the lower of cost (first-in, first-out) or net realizable value, and net of reserves, consisted of the following:
| March 31, 2022 | December 31, 2021 | |||||||
| Raw materials and packaging | $ | $ | ||||||
| Finished goods | ||||||||
| $ | $ | |||||||
The
Company has recorded a reserve for slow moving and potentially obsolete inventory. The reserve at March 31, 2022 and December 31, 2021
was $
| 11 |
NOTE 3 - EQUIPMENT
Equipment, stated at cost, less accumulated depreciation consisted of the following:
| March 31, 2022 | December 31, 2021 | |||||||
| Machinery-technology equipment | $ | $ | ||||||
| Machinery-technology equipment under construction | ||||||||
| Less accumulated depreciation | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Depreciation
expense for the three months ended March 31, 2022 and 2021 was $
NOTE 4 - OPERATING LEASE
At
March 31, 2022, the Company has one operating lease for its headquarters office space in Burbank. The lease commenced on January 1, 2020,
and has a term for
The components of lease expense and supplemental cash flow information related to leases for the period are as follows:
Three months ended March 31, 2022 | ||||
| Lease Cost | ||||
| Operating lease cost (included in selling, general, and administrative expense in the Company’s statement of operations) | $ | |||
| Other Information | ||||
| Cash paid for amounts included in the measurement of lease liabilities for 2021 | $ | |||
| Weighted average remaining lease term – operating leases (in years) | ||||
| Average discount rate – operating leases | % | |||
| At March 31, 2022 | ||||
| Operating leases | ||||
| Long-term right-of-use assets | $ | |||
| Short-term operating lease liabilities | $ | |||
| Long-term operating lease liabilities | ||||
| Total operating lease liabilities | $ | |||
Maturities of the Company’s lease liabilities are as follows:
| Year Ending | Operating Leases | |||
| 2022 (remainder of year) | ||||
| 2023 | ||||
| 2024 | ||||
| Total lease payments | ||||
| Less: Imputed interest | ||||
| Present value of lease liabilities | ||||
| Less current portion | ( | ) | ||
| Operating lease liabilities, long-term | $ | |||
Lease
expense were $
| 12 |
NOTE 5 – NOTES PAYABLE
| March 31, 2022 | December 31, 2021 | |||||||
| (a)
Notes payable secured by equipment (net of deferred finance charge of $ | $ | $ | ||||||
| (b) Note payable, secured by assets-in default | ||||||||
| (c) Note payable, Payroll Protection Loan | ||||||||
| (d) Note payable, Economic Injury Disaster Loan | ||||||||
| (e) Revenue sharing agreement | ||||||||
| (f) Global merchant financing | ||||||||
| (g) Business funding financing | ||||||||
| Total notes payable outstanding | ||||||||
| Current portion | ||||||||
| Long term portion | $ | $ | ||||||
| (a) | ||
| (b) |
| (c) | ||
| (d) | ||
| (e) |
| (f) |
|
| (g) |
|
| 13 |
NOTE 6 – CONVERTIBLE NOTES PAYABLE
Convertible notes payable consisted of the following:
| March 31, 2022 | December 31, 2021 | |||||||
| Unsecured | ||||||||
| (a) Convertible notes with fixed discount percentage conversion prices | $ | $ | ||||||
| Put premiums on stock settled debt | ||||||||
| (b) Convertible notes with fixed conversion prices | ||||||||
| Default penalty principal added | ||||||||
| Total convertible notes principal outstanding | ||||||||
| Debt discount | ( | ) | ( | ) | ||||
| Convertible notes, net of discount and premium | $ | $ | ||||||
| Current portion | ||||||||
| Long-term portion | $ | $ | ||||||
|
(a) |
| (b) |
|
At
December 31, 2021, the net unamortized balance of debt discounts was $
The
debt discounts related to fees and OID are amortized over the life of the related notes or are amortized in full upon the conversion
of the corresponding note to common stock. For the year ended December 31, 2021, debt discounts of $
On
May 4, 2021 (“Effective Date”), the Company entered into a securities purchase agreement (the “SPA”) with
Clifton Royale Apartments, LLC (the “Investor”) pursuant to which the Company issued a
The
maturity date of the Note was
On
September 2, 2020, the Company issued a convertible note (see paragraph a above) having a conversion price less than $
On
December 9, 2020, the Company executed amendments to these notes effective September 30, 2020, which extended the maturity dates
and fixed the conversion price at $ |
| 14 |
During
the three months ended December 31, 2020, the Company issued nine convertible notes with
fixed conversion prices aggregating $
During
the year ended December 31, 2020, debt discount of $ |
Note 7 – DERIVATIVE LIABILITIES AND FINANCIAL INSTRUMENTS
The Company did not derivative liabilities at March 31, 2022 or December 31, 2021.
NOTE 8 – MEZZANINE EQUITY
The Company has determined that its shares of the Series B and Series C convertible preferred stock are conditionally redeemable upon the occurrence of certain events that are not solely within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders; accordingly the Series B and Series C convertible preferred stock are classified as “mezzanine equity” (temporary equity), between liabilities and stockholders’ deficit. The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future. The shares as valued have been classified as mezzanine equity and presented as such on the consolidated balance sheet at March 31, 2022 as single line items due to the immaterial par value. The mezzanine equity value is not included in shareholders’ deficit.
Series B Convertible Preferred Stock
The
terms of the Certificate of Designation of the Series B Convertible Preferred Stock, which was filed with the State of Nevada on January
12, 2021, state that the
On
December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife
Rx”) pursuant to which, the Company agreed to acquire
Series C Convertible Preferred Stock
The terms of the Certificate of Designation of the Series C Convertible Preferred Stock, which was filed with the State of Nevada on January 12, 2021, state that such Series C Convertible shares have a par value of $ per share and a stated value of $ per share (the “Stated Value”) and each Series C Preferred Share shall be convertible into shares of Common Stock (“Conversion Ratio”), at the option of a Holder, at any time and from time to time, from and after the issuance of the Series C Preferred Stock. Anti-dilution terms of the preferred may change the conversion ratio. Each holder of the Series C Preferred Stock shall have the right to vote on any matter that may from time to time be submitted to the Company’s shareholders for a vote, on an as converted basis, either by written consent or by proxy. Additionally, the shareholders are entitled to liquidation benefits including a cash payout, the liquidation terms include sales and mergers affection a change in control.
On January 14, 2021, the Board of Directors of the Company approved the issuance of all authorized shares of Series C Convertible Preferred Stock to the following Medolife Rx Designees:
| Trillium Partners LP | Shares of Series C Preferred Stock |
| Sagittarii Holdings, Inc. | Shares of Series C Preferred Stock |
The stock will be valued on the basis of the greater of the value of the services received or the fair value of the Series C convertible preferred shares issued.
The shares issued to Trillium and Sagittarii were valued based on the conversion number of common shares at the market price on the date of issuance. The shares were valued at $ and were charged to expense for services during the three months ended March 31, 2021.
| 15 |
NOTE 9 – STOCKHOLDERS’ DEFICIT
Common Stock
Common stock issued for cash
During the three months ended March 31, 2022, the Company did not issue any shares of common stock.
Common stock issued for services
During
the three months ended March 31, 2022, the Company issued shares of common stock to service vendors with a fair value of $
Preferred Stock
Series A Preferred Stock
On
April 14, 2020, the Company filed a Certificate of Designation for the Company’s Series A Preferred Stock (“Series A”)
with the Secretary of State of Nevada designating shares of its authorized preferred stock as Series A Preferred Stock, par
value of $ per share. The Series A Preferred Stock is not entitled to receive any dividends or liquidation preference and are not
convertible into shares of the Company’s common stock.
On
April 14, 2020, The Company issued shares of the Series A to the Company’s Chief Executive Officer in a private placement
transaction. The fair value of the stock was determined to be $
On November 16, 2020, the Company entered into a Control Block Transfer Agreement with Eric Rice and Phillip Sands, pursuant to which, Mr. Rice agreed to transfer the shares of the Series A to Mr. Sands. Mr. Rice agreed to transfer the Control Block to Phillip Sands in order to consummate the Company’s transition into a holding company, without requiring the Company to further dilute its stock through the issuance of new shares.
Phil
Sands resigned as an officer and director of the Company on May 10, 2021. Simultaneously therewith, the Company executed a Control Block
Transfer Agreement with Phil Sands and Arthur Mikaelian, pursuant to which, effective Mr. Sands agreed to transfer shares of
the Company’s Series A Super Voting Preferred Stock to Dr. Mikaelian, representing a transfer of majority voting control over
Series B Preferred Stock
On
December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife
Rx”) pursuant to which, the Company agreed to acquire
Series C Convertible Preferred Stock - Description
The
terms of the Certificate of Designation of the Series C Convertible Preferred Stock, which was filed with the State of Nevada on January
12, 2021, state that such
On January 14, 2021, the Board of Directors of the Company approved the issuance of all authorized shares of Series C Convertible Preferred Stock to the following Medolife Rx Designees:
| Trillium Partners LP | Shares of Series C Preferred Stock |
| Sagittarii Holdings, Inc. | Shares of Series C Preferred Stock |
| 16 |
The stock will be valued on the basis of the greater of the value of the services received or the fair value of the Series C convertible preferred shares issued.
Restricted common stock
In 2019, the Company agreed to issue shares of the Company’s common stock with vesting terms to Arthur Mikaelian. . The Company accounts for the share awards using a graded vesting attribution method over the requisite service period, as if each tranche were a separate award. During the three months ended March 31, 2022 and 2021, total share-based expense recognized related to vested restricted shares totaled $-- and $, respectively. At March 31, 2022, there was $ of unvested compensation related to these awards that will be amortized over a remaining vesting period of approximately thru March 2022.
The following table summarizes restricted common stock activity for the three months ended March 31, 2022:
| Number of shares | Fair value of shares | |||||||
| Non-vested shares, December 31, 2021 | ||||||||
| Granted | ||||||||
| Vested | ( | ) | ( | ) | ||||
| Forfeited | ||||||||
| Non-vested shares, March 31, 2022 | $ | |||||||
As of March 31, 2022, no shares have been issued and vested shares are included in shares to be issued on the accompanying financial statements
Common stock issued in conversion of convertible notes payable
During
the three months ended March 31, 2022, the Company issued shares of common stock to holders of convertible notes upon the
conversion of convertible notes payable and accrued interest valued at $
Stock Options
During the three months ended March 31, 2022 and 2021, the Company did not recognize any compensation expense relating to vested stock options.
During the three months ended March 31, 2022, the Company did not issue any options. In April 2020, the Company issued options exercisable into shares of common stock which vested immediately. The options have an exercise price of $ per share, and expire in years. The total fair value of these options at grant date was approximately $, which was determined using the Black-Scholes-Merton option pricing model with the following average assumption: stock price $ per share, expected term ranging from , volatility %, dividend rate of % and risk-fee interest rate of %.
The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.
As of March 31, 2022, the amount of unvested compensation related to stock options was approximately $ which will be recorded as an expense in future periods as the options vest.
| Number of options | Weighted
Average Exercise Price | Contractual Life in Years | ||||||||||
| Options Outstanding as of December 31, 2021 | ||||||||||||
| Granted | ||||||||||||
| Exercised | ||||||||||||
| Forfeited | ||||||||||||
| Options Outstanding as of March 31, 2022 | ||||||||||||
| Options Exercisable as of March 31, 2021 | $ | |||||||||||
At March 31, 2021, the options outstanding had intrinsic value.
NOTE 10 – RELATED PARTY TRANSACTIONS
On
December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife
Rx”) pursuant to which, the Company agreed to acquire
| 17 |
The
Company has an agreement with Dr. Mikaelian in consideration of the Company’s exclusive use of patented technology developed by
Dr. Mikaelian. Pursuant to the agreement, as amended, the Company shall pay a royalty of
On
November 15, 2020, the Company entered into an interim compensation agreement with Mr. Phillip Sands providing for monthly compensation
of $
On
November 16, 2020, the Company entered into a Control Block Transfer Agreement with Eric Rice and Phillip Sands, pursuant to which, Mr.
Rice agreed to transfer shares of the Company’s Series A Super Voting Preferred Stock to Mr. Sands, representing a transfer
of majority voting control over the Company because the holder of such shares of our Series A Super Voting Preferred Stock
automatically carries a vote equal to
For
the three months ended March 31, 2021, the Company recorded revenue of $
During
the three months ended March 31, 2022, the Company recorded administrative expenses of $
NOTE 11 – COMMITMENTS AND CONTINGENCIES
COVID-19
During the period ended March 31, 2022, the COVID-19 pandemic has impacted our operating results and the Company anticipates a continued impact for the balance of the year. In addition, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. The Company monitors guidance from federal, state, and local public health authorities, and has implemented health and safety precautions and protocols in response to these guidelines. The extent of the impact of the COVID-19 pandemic has had and will continue to have on the Company’s business is highly uncertain and difficult to predict and quantify at this time.
Contingencies include obligations for lease agreements, including an abandoned lease space discussed at Note 5, along with the Company current lease for its headquarters office, also discussed in Note 5.
It is management’s opinion that there are no material contingent liabilities that are not disclosed in the financial statements and footnote disclosures as of March 31, 2022.
NOTE 12 – SUBSEQUENT EVENTS
Common Stock Issued
Between January 1, 2022 and May 19, 2022, the Company issued the shares to Dr. Arthur Mikaelian.
| 18 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may”, “will”, “expect”, “believe”, “anticipate”, “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include by are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business relationships.
This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking statements.
Overview
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian, who pioneered the unlaying polarization technology, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company intends to pursue product registration and drug approval in multiple countries.
With its line of AELIA brand products, Medolife manufactures and distributes consumer wellness products in areas such as pain relief, beauty, and general wellness. AELIA products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Medolife’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife could have the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Our Company History
The company was founded in Nevada as Freight Solution, Inc. in 2016.
On June 5, 2018, we underwent a change of control. In connection with the change of control, our board of directors and officers was reconstituted through the resignation of Shane Ludington as Chairman, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of the Registrant and the appointment of Mr. Eric Rice as Chairman, Chief Executive Officer and Chief Financial Officer and Mr. Jeffrey Doiron as President and Chief Operations Officer.
On June 6, 2018 we formed a wholly owned subsidiary, Quanta Acquisition Corp. in the state of California, and executed an Agreement of Merger and Plan of Reorganization, with Bioanomaly, Inc., a California corporation, d/b/a Quanta and Quanta Acquisition Corp., a California corporation and our wholly-owned subsidiary. Pursuant to the terms of the Merger Agreement, Quanta Acquisition Corp. merged with and into Quanta in a statutory reverse triangular merger with Quanta surviving as a wholly owned subsidiary. Following the merger, we adopted our business plan.
On June 6, 2018, we cancelled 15,000,000 shares of common stock acquired through the change in control transaction. As consideration for the merger, we agreed to issue the shareholders of Quanta an aggregate of 21,908,810 shares of our common stock, par value $0.001 per share. Freight Solution shareholders retained 6,500,000 shares of common stock, which represented 23% of our issued and outstanding stock following the merger.
Simultaneously with the merger, we accepted subscriptions for 6,500,000 shares of common stock in a private placement offering at a purchase price of $0.20 per share for an aggregate offering amount of $1,300,000. We also issued two non-affiliated investors warrants to purchase 3,000,000 shares of our common stock at an exercise price of $0.30 per share expiring in four years.
Following the consummation of the merger, Quanta shareholders beneficially owned approximately 63% of our issued and outstanding common stock.
On July 11, 2018 the State of Nevada approved our name change from Freight Solution, Inc. to Quanta, Inc.
On April 14, 2020, we issued to Eric Rice, our former Chairman, Chief Executive Officer and Chief Financial Officer, 2,500,000 shares of a newly created class of preferred stock, Series A Preferred Stock.
On November 16, 2020, the Company entered into a Control Block Transfer Agreement with Eric Rice and Phil Sands, pursuant to which, Mr. Rice agreed to transfer 2,500,000 shares of the Company’s Series A Super Voting Preferred Stock to Mr. Sands, representing a transfer of majority voting control over the Company because the holder of such 2,500,000 shares of our Series A Super Voting Preferred Stock automatically carries a vote equal to 51% on all matters submitted to a vote of the holders of our Common Stock and Preferred Stock. On November 16, 2020, the Company entered into a Share Cancellation Agreement with Eric Rice, holder of 18,030,032 shares of QNTA Common Stock, pursuant to which Mr. Rice agreed to cancel 17,030,032 shares (16,951,432 shares were cancelled December 29, 2020), and to retain ownership of 1,000,000 shares of Common Stock.
On December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife”) pursuant to which, the Company agreed to acquire 51% of Medolife in exchange for 9,000 shares of newly created Series B Convertible Preferred Stock. On January 14, 2021, we completed our acquisition of 51% of Medolife and Medolife’s founder, Arthur Mikaelian, PhD, a member of our Board of Directors, officially replaced Phil Sands as our Chief Executive Officer. Phil Sands resigned as an officer and director of the Company on May 10, 2021. Simultaneously therewith, the Company executed a Control Block Transfer Agreement with Phil Sands and Arthur Mikaelian, pursuant to which, effective Mr. Sands agreed to transfer 2,500,000 shares of the Company’s Series A Super Voting Preferred Stock to Dr. Mikaelian, representing a transfer of majority voting control over the Company because the holder of such 2,500,000 shares of our Series A Super Voting Preferred Stock automatically carries a vote equal to 51% on all matters submitted to a vote of the holders of our Common Stock and Preferred Stock. Mr. Sands agreed to transfer the Control Block to Arthur Mikaelian in exchange for 3,000,000 shares of the Company’s Common Stock, and for the payment of $22,500 in accrued salary, as well as the payment of health insurance benefits through January of 2022.
| 19 |
Medolife provides contract research services. The Company focuses on research, development, and production of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals utilizing patented polarization technology. Medolife Rx serves clients in the United States.
In 2007, Medolife began its venom-to-drug research and development concept. In 2008, Medolife identified the Rhopalurus princeps scorpion species, which are endemic to the Dominican Republic, as a possible candidate. The company entered into an agreement with the local Ministry of Environment and Natural Resources to investigate the anticancer properties of scorpion venom peptides. The Company’s research confirmed the anticancer properties of the peptide. That same year, Medolife registered its product, Escozine, in the Dominican Republic due to the prime material and preliminary studies originating from Dominican Republic. Escozine was registered under Sanitary Registry Number PN2010-0244 as an anti-tumoral alternative medicine in the Dominican Republic, which allowed the company to perform clinical studies and observations in the country.
Quanta, which entered the CBD pain-relief rub market (“Muscle Rub”), is the first in a series of products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized ingredient creates stronger bonds with the body’s receptors providing higher bioavailability. The company believes this natural solution has nearly limitless applications in the world of plant-based consumer products.
In early 2020, the company was preparing to apply to the FDA to initiate the approval process for Escozine as an orphan drug for pancreatic cancer. The Weinberg Group was hired as our regulatory compliance consultants for the FDA application and guidelines.
As the COVID-19 pandemic spread during the Spring of 2020, Medolife studied the scorpion venom peptide as a potential COVID-19 drug treatment and began confirming its antiviral properties. The company applied to the FDA as a Pre-Investigational New Drug (PIND), which opened PIND #150335. For PIND Submission and Clinical Trial Strategy in the United States and the Dominican Republic, Medolife has contracted Affinity Bio Partners as a consulting firm on FDA regulatory matters.
In August of 2020, Medolife initiated clinical studies at the Cruz Jiminian Clinic (Clinica Cruz Jiminian) in Santo Domingo, Dominican Republic, which is a clinic with a license allowing them to treat COVID-19 patients. The study included 450 COVID-19 patients. The observation contained more female than male patients, with 252 female and 198 male participants. Out of 450 participants, there was an even spread among the age groups, with a higher number in the 41-to-50-year-old group.
EFFICACY STUDY.
Escozine was used as a 3-pillar treatment: a Therapeutic, a Palliative, and a Preventative.
Therapeutic
| ● | Escozine was used as a monotherapy | |
| ● | All therapeutic participants were tested COVID-19 positive prior to observation. | |
| ● | 100% of patients were discharged with a negative COVID-19 test result within 7 to 10 days of treatment with Escozine. |
Conclusion: Within 4-5 days, all COVID-19 patients using Escozine tested negative for the virus, indicating Escozine eliminated the COVID-19 virus or accelerated recovery.
Palliative
| ● | COVID-19 positive patients report a dramatic decrease of symptoms within 2-4 days of Escozine treatments. The World Health Organization Quality of Life (“WHOQOL”) Bref quality of life questionnaire by the World Health Organization (WHO) was used since July 2020 to evaluating symptoms in patients, including: |
| ○ | Shortness of breath | |
| ○ | Pain | |
| ○ | Fatigue | |
| ○ | Headache | |
| ○ | Loss of taste | |
| ○ | Fever | |
| ○ | Loss of smell (anosmia) |
| 20 |
Conclusion: All participants reported significant improvement on all their COVID-19-related symptoms within 5 days, indicating that Escozine can be used to treat the symptoms of COVID-19.
Preventative
| ● | Transmission of virus to treating physicians and nurses of COVID-19 patients is inhibited upon administering Escozine. | |
| ● | Substantial reduction in infectability and spread of the SARS-CoV-2 virus. |
Conclusion: All hospital workers remained healthy during the clinical observation while taking Escozine, indicating that Escozine can be used as a preventative measure for COVID-19. The preventative capabilities require additional study.
SAFETY STUDY.
To verify the safety of using Escozine, patients were tested before and after treatment for:
| ● | Hematology | |
| ● | Clinical chemistry (Kidney and Liver function tests, Enzymes, Glucose, Calcium and Phosphorus) | |
| ● | Urine | |
| ● | CD4/CD8 |
Conclusion: No toxic response was observed in 100% of patients and no side-effects were reported, indicating that Escozine is safe to use for COVID-19 patients.
ADDITIONAL FINDINGS.
During the clinical study, Medolife observed that Escozine prevents Acute Kidney Injury (AKI) caused by COVID-19:
| ● | During the clinical study, no deaths occurred. | |
| ● | 40% of the monitored COVID-19 patients who were administered Escozine, had serum creatinine that was higher than normal, indicating AKI before Escozine administration. | |
| ● | After Escozine administration, most of the patient’s creatinine concentrations dropped or did not change. | |
| ● | Overall, the frequency of patients that developed normal creatinine levels after Escozine administration was statistically significant (p<0.05). |
| ● | Medolife has received a new reply from the FDA on their latest submission of requested data. In the reply, the FDA: |
| ● | Stated that they acknowledge the Company’s clinical trial as an informal proof-of-concept study | |
| ● | Laid out very specific guidelines for the next steps required by the regulatory body in order to garner approval for Escozine as a treatment for COVID-19, in which the FDA requested: |
| ○ | Pharmacokinetic (PK) study, which Medolife has initiated in the United Kingdom. | |
| ○ | DNA toxicology study, for which Medolife is negotiating with a GLP certified laboratory in the United States. | |
| ○ | Additional Chemistry, Manufacturing and Controls (CMC) data from Medolife’s contract manufacturer, CURE Pharmaceutical Corporation. |
R&D Expenses related to Escozine.
Over the last 24 months, the company has spent more than $533,000 on research and development related to Escozine as both a treatment of cancer and for COVID-19.
| 21 |
Quanta Basics
Quanta and its subsidiary Medolife are cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, the company supports product formulations in cancer and COVID-19 treatments, as well as pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, the company’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind the company’s polarization process has many potential applications. From potentiating bio-ingredients to produce more-effective carbon-trapping plants to transformative anti-aging solutions the company’s technology has the opportunity to upend how commercial products are made and the benefits from them. Already we see multi-trillion-dollar global industries benefiting from the company’s technology.
Our proof of concept, the company’s market-leading CBD pain-relief rub (“Muscle Rub”), is only the first in a series of paradigm shift products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized active ingredient is more soluble and creates stronger bonds with the body’s receptors. This allows us to enhance ingredients so they work faster and more powerfully without the use of chemical by-products or cellular penetration. the company believes this natural solution has nearly limitless applications in the world of plant-based consumer products.
The company is involved in ambitious projects that we believe will reshape the next wave of climate science, sustainability, nutrition, and more. Having harnessed the technology of the future, the company is dedicated to bringing tomorrow’s health and wellness solutions to the billions in need today.
Discovery Synopsys
Using our product development process and business-to-business and direct-to-consumer sales approaches as a benchmark for future business, we developed the Quanta business model. The company believes that its technology unique ability to strengthen ingredients renders them more potent without added chemicals or penetrating cells means Quanta is in a first-of-its-kind position in the market. As the world’s first company focused on Quantum Biology we sit in a strong, but unique position in the market.
Upcoming products and ventures will be designed to achieve or surpass this level of consumer benefit and uptake.
Quanta Business Model in 3 P’s: Potentiation, Partners, and Profits
After two years we believe the best possible model for the long-term success of the company is collaborating with best-in-class partners through joint ventures for new verticals, products, and research. These joint ventures may involve a jointly owned special purpose entity or they may be entirely based on contractual obligations.
The unique ability to increase the ingredient and product performance opens the doors for major opportunities. Higher performing ingredients mean less is needed to make a strong impact (increased margins, increase overall efficacy). We proved this with our Muscle Rub, which uses approximately 1/3 the CBD of competing products with demonstrably improved results.
The level of potentiation delivered by Quanta allows our partners the unique ability to provide higher-performing products, lower material costs, more competitive pricing and increased profit margins. In short, our partners will be able to make better performing, more affordable products with a higher repeat purchase. This is true disruption and consumer utopia.
We aim to work with groups that specialize in manufacturing, marketing, selling and distributing existing product lines that utilize ingredients we can potentiate. Partners like this facilitate efficient market delivery of joint innovations.
We believe this strategy provides greater shareholder value, enhances revenue potential, defrays upfront expenses and affords us the ability to raise capital.
Ultimately, these ventures would result in licensing out our technology to other reputable brands and companies to create co-branded products whereas the term “Powered by Quanta” becomes as recognized as “Intel Inside.”
We believe this type of partnership will afford a company Quanta partners with:
| ● | Development of emerging products with cutting edge ingredients. | |
| ● | A product line with a true point of differentiation. | |
| ● | New SKUs with an increased margin. | |
| ● | Decreased cost of goods sold. |
| 22 |
Simultaneously these partnerships can allow Quanta:
| ● | Greater brand recognition. | |
| ● | Increased revenue and in turn profitability. | |
| ● | Quicker timeline to more licensing opportunities because of a track record of success. | |
| ● | Brand to become synonymous with improving the performance of ingredients within products. |
Manufacturing Partnerships -
Quanta is currently focused on partnering with large-scale manufacturers and distributors able to produce products that meet the requirements of applicable regulations IE: Good Manufacturing Practices to fulfill orders of our own product line. This type of partnership is crucial because it will afford:
| ● | New product development that meets certification requirements | |
| ● | Much larger production scale | |
| ● | Speed to market | |
| ● | Increased distribution and profitability |
With our licensing capabilities, Quanta believes this technology can render better, more efficacious products that cost less to create but command a higher purchase value because of polarized ingredients. This, in turn, allows companies to diversify their catalog of products while simultaneously providing them with a distinguished advantage. More efficacious ingredients.
Government Regulation
We believe we are in compliance with applicable federal, state and other regulations and that we have compliance programs in place to ensure compliance going forward. There are no regulatory notifications or actions pending.
Results of Operations
Summary of Key Results
Results of Operations for three months ended March 31, 2022 compared to the three months ended March 31, 2021.
Revenue
Net sales are comprised of wholesale sales to our retail partners and sales through our direct-to-consumer channel. Net sales in both channels reflect the impact of product returns as well as discounts for certain sales programs or promotions.
For the three months ended March 31, 2022, the Company recognized $63,233 in net sales. For the three months ended March 31. 2022, the Company recognized $318,807 in net sales.
Expenses
Operating expenses for the three months ended March 31, 2022 was $859,189, including $105,000 in research and development costs, and $747,797 in selling, administrative, and $6,394 in employee compensation and benefits and other costs associated with operations.
Operating expenses for the three months ended March 31, 2021 was $3,276,524, including $130,825 in research and development costs, and $3,016,277 in selling, administrative, and $129,422 in employee compensation and benefits and other costs associated with operations.
Other Income (Expense)
For the three months ended March 31, 2022, the Company recognized $(124,831) of net other expenses.
For the three months ended March 31, 2021, the Company recognized $(99,762) of net other expenses.
Net Loss
Net loss for the three months ended March 31, 2022 was $942,104. Net loss for the three months ended March 31, 2021 was $2,948,486. No provision for income taxes for either period was recorded.
| 23 |
Going Concern
We have yet to establish any history of profitable operations. For the three months ended March 31, 2022, the Company incurred a net loss of $949,154 and used cash in operating activities of $249,499, and at March 31, 2022, the Company had a working capital deficiency of $4,560,737. These factors raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. The going concern opinion could materially limit our ability to raise additional funds through the issuance of new debt or equity securities, and future reports on our financial statements may also include an explanatory paragraph with respect to our ability to continue as a going concern.
At March 31, 2022, the Company had cash on hand in the amount of $7,786. The Company’s ability to continue as a going concern is dependent upon improving its profitability and the continuing financial support from its shareholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company’s obligations as they become due. No assurance can be given that any future financing if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company can obtain additional financing, if needed, it may contain undue restrictions on its operations, in the case of debt financing, or cause substantial dilution for its stockholders, in the case of equity financing
Critical Accounting Policies and Estimates
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. GAAP requires us to make estimates and assumptions that affect the reported amounts in our financial statements including various allowances and reserves for accounts receivable and inventories, the estimated lives of long-lived assets and trademarks and trademark licenses, as well as claims and contingencies arising out of litigation or other transactions that occur in the normal course of business. The following summarizes our most significant accounting and reporting policies and practices:
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, impairment analysis of long-term assets, valuation allowance on deferred income taxes, assumptions used in valuing stock instruments issued for services, assumptions made in valuing derivative liabilities, and the accrual of potential liabilities. Actual results may differ from these estimates.
Revenue Recognition
Product Sales—Substantially all of the Company’s revenue is derived from product sales. Product revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time.
License revenue— Revenue from symbolic IP is recognized over the access period to the Company’s IP (see Note 2).
Cost of goods sold includes direct costs and fees related to the sale of our products.
Stock Compensation
The Company periodically issues stock options, warrants, shares of common stock, and restricted stock unit awards, as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation (Topic 718). Stock-based compensation cost for employees is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the requisite service period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.
Recently Issued Accounting Pronouncements
See Note 1 to the Condensed Consolidated Financial Statements
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of March 31, 2022 that our disclosure controls and procedures were not effective.
| 24 |
We identified material weaknesses in our internal controls over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. The matters involving internal controls and procedures that our management considered to be material weaknesses were: (i) we had an insufficient number of personnel appropriately qualified to perform control design, execution and monitoring activities; (ii) we did not have written documentation of our internal control policies and procedures, including written policies and procedures to ensure the correct application of accounting and financial reporting with respect to the current requirements of U.S. GAAP and SEC disclosure requirements; (iii) we had ineffective controls over our financial statement close and reporting process and did not provide reasonable assurance that accounts were complete and accurate and agreed to detailed support and that reconciliations of accounts were properly performed, reviewed and approved, (iv) we did not maintain effective controls over the recording and approval of recurring and non-recurring journal entries and (v) we had inadequate segregation of duties consistent with control objectives.
Changes in Internal Control over Financial Reporting
There were no changes in internal control over financial reporting (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we are a party to, or otherwise involved in, legal proceedings arising in the normal and ordinary course of business.
On April 30, 2021, the Company was served with an Entry of Default pursuant to two Product Loan Agreements executed between the Company and individuals Jason Brooks and Bruce Hofert, respectively, on July 9, 2020.
On June 30, 2021, the Company has been summoned by the Iowa District Court for Sioux County, pursuant to a Product Loan Agreement executed between the Company and B&L Investments, LLC, on July 7, 2020.
On August 5, 2021, the Company received notice the Securities and Exchange Commission had commenced an investigation related to the Company and affiliated persons and entities. The Company is cooperating with the Commission.
We are not aware of any other proceeding, threatened or pending, against us which, if determined adversely, would have a material effect on our business, results of operations, cash flows or financial position.
Item 1A. Risk Factors.
The recent global coronavirus outbreak could harm our business and results of operations.
The global outbreak of COVID-19 has negatively affected the U.S. and global economies, and has negatively impacted businesses, workforces, customers, and created significant volatility of financial markets. It has also disrupted the normal operations of many businesses, including ours. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration and severity of the outbreak, the length of restrictions and business closures, and the impact on capital and financial markets, all of which are highly uncertain and cannot be predicted. This outbreak could decrease spending, adversely affect demand for our products and harm our business and results of operations. In the quarter ended September 30, 2020, we believe the COVID-19 pandemic did impact our operating results as shipments to customers in the second quarter were down 13% from the first quarter of the year. However, we have not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic. While it is not possible at this time to estimate the full impact that COVID-19 will have on our business, restrictions resulting from COVID-19 on general economic conditions could, among other things, impair our ability to raise capital when needed. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
No unregistered sales of equity securities subsequent to March 31, 2022.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
| 25 |
Item 5. Exhibits.
The following exhibits are incorporated into this Form 10-Q Quarterly Report:
* Filed along with this document
| 26 |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| QUANTA, INC | ||
| Dated: May 23, 2022 | By: | /s/ Arthur Mikaelian |
Arthur Mikaelian | ||
| President, Chairman, Director and Chief Executive Officer | ||
| (Principal Executive Officer and Interim Principal Financial Officer) | ||
| 27 |